https://www.selleckchem.com/pr....oducts/d-lin-mc3-dma
A review on the current evidence of the efficacy and security of liposomal amphotericinB (L-Am for the treatment of visceral leishmaniasis (VL) has been performed. In the Indian subcontinent, a single dose of 10mg/kg has shown effectiveness in the treatment of VL due to Leishmania donovani. In contrast, higher doses of L-AmB (up to 30mg/kg) are required in Africa to treat a VL of the same etiology. When treating VL by Leishmania infantum acquired in the Americas and Europe the usual dose of L-AmB is 20-21mg/kg. In HIV co-infecte
Like
Comment
Share
